Travere Corp (TVTX): רווח נקי למניה (EPS TTM)

TVTX (Travere Therapeutics) - סמל מסחרי של החברה

The rolling annual earnings per share of Travere Therapeutics (TVTX), as shown on the GURU.Markets platform chart, is based on the company's ethical approach to hiring specialized experts. Management is currently scaling commercial sales, and the value of -1.66 characterizes this level. However, fierce competition in the rare kidney disease niche turns drug development into a risky race, where finishing second threatens the loss of all investments.

TVTX רווח למניה ב-12 החודשים האחרונים Travere Corp (04.07.2022 - 18.11.2026)

פילוחים אנליטיים ודוחות נתונים של חברת Travere Therapeutics (TVTX)

אנליטיקה מסכמת של החברה:TVTX - Travere Therapeutics, Inc.
סחורת הדגל של Travere Corp

A comparative asset analysis requires an assessment of the actual earnings per share, calculated as the ratio of total annual net income to the number of shares outstanding. For Travere Therapeutics (TVTX), this 12-month net income per share chart reflects a transition from development costs to operational efficiency as drug sales scale.